OBI Pharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	759.33	1,732	899.28	4,741	2,512
Short-Term Investments	427	1,399	1,883	30.71	140
Trading Asset Securities	-	0.09	0.23	0.75	1.77
Cash & Short-Term Investments	1,186	3,131	2,782	4,773	2,654
Cash Growth	-62.11%	12.53%	-41.70%	79.83%	-28.69%
Accounts Receivable	12.71	4.2	6.48	2.04	3.47
Other Receivables	54.15	246.34	225.86	26.24	19.8
Receivables	66.86	250.54	232.34	28.27	23.27
Inventory	18.43	27.73	25.93	21.97	9.56
Prepaid Expenses	308.46	30.68	26.38	211.26	167.35
Other Current Assets	-	-	100.34	-	-
Total Current Assets	1,580	3,440	3,167	5,034	2,854
Property, Plant & Equipment	994.29	1,165	1,249	1,176	1,149
Long-Term Investments	763.74	959.85	1,070	8.73	9.11
Goodwill	-	-	-	61.15	61.15
Other Intangible Assets	46.86	62.84	73.18	321.29	337.14
Other Long-Term Assets	36.29	26.13	51.64	32.9	76.21
Total Assets	3,421	5,654	5,611	6,634	4,487
Accounts Payable	0.99	3.44	0.77	1.14	0.53
Accrued Expenses	-	251.9	65.76	112.49	177.82
Short-Term Debt	50.35	0.41	4.31	15.71	-
Current Portion of Long-Term Debt	74.3	34.09	7	7	7
Current Portion of Leases	54.02	55.12	49.86	40.35	52.07
Current Income Taxes Payable	2.46	10.39	1.58	0.56	0.34
Current Unearned Revenue	2.29	7.78	6.29	3.16	-
Other Current Liabilities	166.16	49.24	30.28	40.73	89.47
Total Current Liabilities	350.56	412.37	165.84	221.14	327.22
Long-Term Debt	29.46	48.22	60.06	67.07	28
Long-Term Leases	309.98	366.79	425.89	163.03	205.96
Long-Term Deferred Tax Liabilities	-	-	-	46.33	54.76
Other Long-Term Liabilities	6.14	6.01	5.89	0	-
Total Liabilities	696.13	833.39	657.67	497.57	615.95
Common Stock	1,316	2,632	2,294	2,294	1,993
Additional Paid-In Capital	9,204	9,101	7,128	6,933	3,702
Retained Earnings	-8,616	-7,879	-5,569	-4,523	-2,909
Treasury Stock	-	-26.53	-26.53	-45.99	-45.99
Comprehensive Income & Other	-15.55	-12.09	-19.87	-26.32	-24.53
Total Common Equity	1,889	3,815	3,807	4,632	2,716
Minority Interest	836.58	1,006	1,147	1,504	1,155
Shareholders' Equity	2,725	4,820	4,953	6,136	3,871
Total Liabilities & Equity	3,421	5,654	5,611	6,634	4,487
Total Debt	518.11	504.63	547.11	293.15	293.03
Net Cash (Debt)	668.23	2,626	2,235	4,479	2,361
Net Cash Growth	-74.56%	17.49%	-50.10%	89.73%	-32.08%
Net Cash Per Share	5.08	22.48	19.52	40.33	23.73
Filing Date Shares Outstanding	131.64	131.48	114.62	114.55	99.47
Total Common Shares Outstanding	131.64	131.48	114.62	114.55	99.47
Working Capital	1,230	3,027	3,001	4,813	2,527
Book Value Per Share	14.35	29.01	33.21	40.44	27.30
Tangible Book Value	1,842	3,752	3,734	4,250	2,318
Tangible Book Value Per Share	13.99	28.53	32.57	37.10	23.30
Land	-	-	-	87.51	87.51
Buildings	-	344.49	343.2	370.02	329.28
Machinery	-	1,080	1,022	1,054	671.26
Construction In Progress	-	10.07	66.46	35.74	368.45
Leasehold Improvements	-	276.85	181.24	184.06	65.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.